Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Malignant Lymphoma

  Free Subscription


1 Biochem Biophys Res Commun
2 Blood
2 Br J Dermatol
1 Br J Haematol
1 Cancer
2 Haematologica
1 J Clin Oncol
1 J Immunol
1 Lab Invest
3 Leuk Lymphoma
1 Leukemia

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Biochem Biophys Res Commun

  1. WANG N, Zeng GZ, Yin JL, Bian ZX, et al
    Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma.
    Biochem Biophys Res Commun. 2019 Sep 16. pii: S0006-291X(19)31744.
    PubMed     Text format     Abstract available


  2. KHATRI SS, Kim AS
    Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma.
    Blood. 2019;134:993.
    PubMed     Text format    

  3. HILTON LK, Tang J, Ben-Neriah S, Alcaide M, et al
    --The double hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
    Blood. 2019 Sep 16. pii: blood.2019002600. doi: 10.1182/blood.2019002600.
    PubMed     Text format     Abstract available

    Br J Dermatol

  4. RITCHIE S, Qureshi I, Molloy K, Yoo J, et al
    Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T cell lymphoma at a tertiary care centre: Should we avoid chemotherapy in conditioning regimes?
    Br J Dermatol. 2019 Sep 19. doi: 10.1111/bjd.18541.
    PubMed     Text format     Abstract available

  5. ENGELINA S, Saggu M, Yoo J, Shah F, et al
    Brentuximab a novel antibody therapy: Real-World Use Confirms Efficacy and Tolerability for CD30 positive cutaneous lymphoma.
    Br J Dermatol. 2019 Sep 16. doi: 10.1111/bjd.18535.
    PubMed     Text format     Abstract available

    Br J Haematol

  6. DEPAUS J, Delcourt A, Andre M
    Therapeutic recommendations for early stage Hodgkin lymphomas.
    Br J Haematol. 2019;184:9-16.
    PubMed     Text format     Abstract available


  7. BLOOMHARDT HM, Sint K, Ross WL, Rotatori J, et al
    Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health.
    Cancer. 2019 Sep 19. doi: 10.1002/cncr.32512.
    PubMed     Text format     Abstract available


  8. TOWNSEND W, Pasikowska M, Yallop D, Phillips EH, et al
    The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T-cells.
    Haematologica. 2019 Sep 19. pii: haematol.2019.220160.
    PubMed     Text format     Abstract available

  9. FERRERO S, Rossi D, Rinaldi A, Bruscaggin A, et al
    KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
    Haematologica. 2019 Sep 19. pii: haematol.2018.214056.
    PubMed     Text format     Abstract available

    J Clin Oncol

  10. KAHN JM, Kelly KM, Pei Q, Bush R, et al
    Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study.
    J Clin Oncol. 2019 Sep 20:JCO1900812. doi: 10.1200/JCO.19.00812.
    PubMed     Text format     Abstract available

    J Immunol

  11. ZHANG Q, Wang HY, Liu X, Nunez-Cruz S, et al
    Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    J Immunol. 2019 Sep 18. pii: jimmunol.1801327. doi: 10.4049/jimmunol.1801327.
    PubMed     Text format     Abstract available

    Lab Invest

  12. YAMAMOTO K, Abe S, Honda A, Hashimoto J, et al
    Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma.
    Lab Invest. 2019 Sep 16. pii: 10.1038/s41374-019-0318.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

    Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country.
    Leuk Lymphoma. 2019 Sep 19:1-7. doi: 10.1080/10428194.2019.1665666.
    PubMed     Text format     Abstract available

  14. HU B, Nastoupil LJ, Loghavi S, Westin JR, et al
    De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
    Leuk Lymphoma. 2019 Sep 18:1-9. doi: 10.1080/10428194.2019.1663418.
    PubMed     Text format     Abstract available

  15. NAKAYAMA S, Morita Y, Espinoza JL, Rai S, et al
    Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia.
    Leuk Lymphoma. 2019 Sep 18:1-3. doi: 10.1080/10428194.2019.1665665.
    PubMed     Text format    


  16. STAIGER AM, Altenbuchinger M, Ziepert M, Kohler C, et al
    A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
    Leukemia. 2019 Sep 17. pii: 10.1038/s41375-019-0573.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.